Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Price:
12.79
USD
0.95%
Market Cap:
$1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
US |
|
H
|
Horizon Global Corp
F:2H6
|
US |
|
Valsoia SpA
MIL:VLS
|
IT |
|
M
|
Massimo Group
NASDAQ:MAMO
|
US |
|
A
|
Aegon NV
MIL:AGN
|
NL |
|
G
|
Genematrix Inc
KOSDAQ:109820
|
KR |
|
Wahana Ottomitra Multiartha Tbk PT
IDX:WOMF
|
ID |
|
Land & Homes Group Ltd
ASX:LHM
|
AU |
|
TV Today Network Limited
BSE:532515
|
IN |
|
Uroica Precision Information Engineering Co Ltd
SZSE:300099
|
CN |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
US |
|
Jyske Bank A/S
CSE:JYSK
|
DK |
|
Ozaurum Resources Ltd
ASX:OZM
|
AU |
|
Butn Ltd
ASX:BTN
|
AU |
|
G
|
Gilat Telecom Global Ltd
TASE:GLTL
|
IL |
|
C
|
China Satellite Communications Co Ltd
SSE:601698
|
CN |
|
J
|
Jervois Global Ltd
XTSX:JRV
|
AU |
|
First Solar Inc
NASDAQ:FSLR
|
US |
Multiples-Based Value
The Multiples-Based Value of one
PHAT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 12.79 USD,
Phathom Pharmaceuticals Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PHAT Multiples-Based Value
LOCKED
Multiples Across Competitors
PHAT Competitors Multiples
Phathom Pharmaceuticals Inc Competitors
Phathom Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
913.4m USD | 5.2 | -4.1 | -8.4 | -8.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.4 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 5.9 | 26.8 | 17.2 | 22 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.5B GBP | 5.2 | 29.8 | 16.5 | 23.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.1B CHF | 5 | 20.2 | 12.5 | 16.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.7 | 11.1 | 8.2 | 9.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
86.5B GBP | 2.6 | 15.1 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
